SCHEMBL6421580

SCHEMBL6421580

CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC[C@H](O)CO

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.65
KDM4E B2RXH2 1/20 0.62
APOBEC3A P31941 1/20 0.62
APOBEC3G Q9HC16 1/20 0.62
GAA P10253 1/20 0.61
ALDH1A1 P00352 4/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
NTSR1 P30989 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
MAPT P10636 1/20 0.54
CYP1A2 P05177 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
XBP1 P17861 1/20 0.53
CYP2C19 P33261 1/20 0.53
TRPA1 O75762 2/20 0.43
TRPM8 Q7Z2W7 2/20 0.43
P2RX4 Q99571 1/20 0.43
EPHX1 P07099 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1618053 1.00 LMNA (0.65) LMNAKDM4EAPOBEC3AAPOBEC3GGAA
SCHEMBL14580754 1.00 LMNA (0.65) LMNAKDM4EAPOBEC3AAPOBEC3GGAA
SCHEMBL10014116 1.00 LMNA (0.65) LMNAKDM4EAPOBEC3AAPOBEC3GGAA
SCHEMBL14565715 1.00 LMNA (0.65) LMNAKDM4EAPOBEC3AAPOBEC3GGAA
SCHEMBL1618051 1.00 LMNA (0.65) LMNAKDM4EAPOBEC3AAPOBEC3GGAA
SCHEMBL1617431 1.00 LMNA (0.65) LMNAKDM4EAPOBEC3AAPOBEC3GGAA
SCHEMBL15144383 1.00 LMNA (0.65) LMNAKDM4EAPOBEC3AAPOBEC3GGAA
SCHEMBL110177 1.00 LMNA (0.65) LMNAKDM4EAPOBEC3AAPOBEC3GGAA
SCHEMBL4749641 1.00 LMNA (0.65) LMNAKDM4EAPOBEC3AAPOBEC3GGAA
SCHEMBL19809887 1.00 LMNA (0.65) LMNAKDM4EAPOBEC3AAPOBEC3GGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10028920-B2 Methods for treating occular irritation involving tearing by administering modulators of TRPM8 UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE (ES) 2018-07-24 US disclosed
US-10028920-B2 Methods for treating occular irritation involving tearing by administering modulators of TRPM8 UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE (ES) 2018-07-24 US disclosed
US-9901549-B2 Method for treating vaginal dryness by administering transient receptor potential cation channel subfamily M member 8 (TRPM8) receptor agonists UNIVERSIDAD MIGUEL HERNÁNDEZ DE ELCHE (ES) 2018-02-27 US disclosed
US-20170071875-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS C.S.I.C. (ES) 2017-03-16 US disclosed
US-20170071875-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS C.S.I.C. (ES) 2017-03-16 US disclosed
US-20170049728-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS C.S.I.C. (ES) 2017-02-23 US disclosed
US-20170049728-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS C.S.I.C. (ES) 2017-02-23 US disclosed
US-9433679-B2 Use of TRMP8 for treating opthalmic diseases or conditions involving tearing UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE (ES) 2016-09-06 US disclosed
US-9433679-B2 Use of TRMP8 for treating opthalmic diseases or conditions involving tearing UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE (ES) 2016-09-06 US disclosed
US-20150313854-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE (ES) 2015-11-05 US disclosed
US-20150313854-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE (ES) 2015-11-05 US disclosed
US-9095609-B2 Ophthalmic composition comprising ws-12 and methods to treat xerophthalmia UNIVERSIDAD MIGUEL HERNÁNDEZ DE ELCHE (ES) 2015-08-04 US disclosed
US-9095609-B2 Ophthalmic composition comprising ws-12 and methods to treat xerophthalmia UNIVERSIDAD MIGUEL HERNÁNDEZ DE ELCHE (ES) 2015-08-04 US disclosed
US-20130245231-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS C.S.I.C. (ES) 2013-09-19 US disclosed
US-20130245231-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS C.S.I.C. (ES) 2013-09-19 US disclosed
WO-2008138162-A1 COMPOSITIONS AND THEIR USE GIVAUDAN SA (CH) 2008-11-20 WO disclosed
US-6956139-B2 (1R, 2S, 5R)-3-1-menthoxyalkan-1-OL cooling sensate TAKASAGO INTERNATIONAL CORPORATION (JP) 2005-10-18 US disclosed
US-20020198412-A1 (1R, 2S, 5R)-3-1-menthoxyalkan-1-OL cooling sensate GREEN CARTER B (US) 2002-12-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028920-B2 Methods for treating occular irritation involving tearing by administering modulators of TRPM8 TRPM8, TRPM5, TRPM7 LMNA 3957/4885KDM4E 3563/4885APOBEC3A 4581/4885
US-20170049728-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE TRPM8, TRPM7, TRPM5 LMNA 3812/4885KDM4E 4269/4885APOBEC3A 4624/4885
US-20020198412-A1 (1R, 2S, 5R)-3-1-menthoxyalkan-1-OL cooling sensate TAS1R1, TAS2R1, TAS1R3 LMNA 3297/4885KDM4E 2626/4885APOBEC3A 4019/4885
US-20150313854-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE TRPM8, TRPM7, TRPM5 LMNA 3812/4885KDM4E 4269/4885APOBEC3A 4624/4885
US-20170071875-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE TRPM8, TRPM7, TRPM5 LMNA 3812/4885KDM4E 4269/4885APOBEC3A 4624/4885
US-20130245231-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE TRPM8, TRPM7, TRPM5 LMNA 3812/4885KDM4E 4269/4885APOBEC3A 4624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.